368 related articles for article (PubMed ID: 25192738)
21. Activity of Ceftazidime-Avibactam against Extended-Spectrum- and AmpC β-Lactamase-Producing Enterobacteriaceae Collected in the INFORM Global Surveillance Study from 2012 to 2014.
Karlowsky JA; Biedenbach DJ; Kazmierczak KM; Stone GG; Sahm DF
Antimicrob Agents Chemother; 2016 May; 60(5):2849-57. PubMed ID: 26926635
[TBL] [Abstract][Full Text] [Related]
22. Nosocomial outbreak by Proteus mirabilis producing extended-spectrum beta-lactamase VEB-1 in a Korean university hospital.
Kim JY; Park YJ; Kim SI; Kang MW; Lee SO; Lee KY
J Antimicrob Chemother; 2004 Dec; 54(6):1144-7. PubMed ID: 15546971
[TBL] [Abstract][Full Text] [Related]
23. Antimicrobial susceptibility of clinical Enterobacteriaceae isolates at the emergency department in a regional hospital: A threat of extended spectrum beta-lactamase-producers among nursing home residents.
Liu HC; Hung YP; Lin HJ; Liu HC; Lee JC; Wu YH; Li CW; Li MC; Ko WC
J Microbiol Immunol Infect; 2016 Aug; 49(4):584-90. PubMed ID: 26692184
[TBL] [Abstract][Full Text] [Related]
24. Laboratory identification, risk factors, and clinical outcomes of patients with bacteremia due to Escherichia coli and Klebsiella pneumoniae producing extended-spectrum and AmpC type β-lactamases.
Tsui K; Wong SS; Lin LC; Tsai CR; Chen LC; Huang CH
J Microbiol Immunol Infect; 2012 Jun; 45(3):193-9. PubMed ID: 22580086
[TBL] [Abstract][Full Text] [Related]
25. Distribution and antimicrobial susceptibility profile of extended-spectrum β-lactamase-producing Proteus mirabilis strains recently isolated in Japan.
Kanayama A; Kobayashi I; Shibuya K
Int J Antimicrob Agents; 2015 Feb; 45(2):113-8. PubMed ID: 25182712
[TBL] [Abstract][Full Text] [Related]
26. Epidemiology of extended-spectrum β-lactamase, AmpC, and carbapenemase production in Proteus mirabilis.
Datta P; Gupta V; Arora S; Garg S; Chander J
Jpn J Infect Dis; 2014; 67(1):44-6. PubMed ID: 24451101
[TBL] [Abstract][Full Text] [Related]
27. In vitro activity of flomoxef and comparators against Escherichia coli, Klebsiella pneumoniae and Proteus mirabilis producing extended-spectrum β-lactamases in China.
Yang Q; Zhang H; Cheng J; Xu Z; Xu Y; Cao B; Kong H; Ni Y; Yu Y; Sun Z; Hu B; Huang W; Wang Y; Wu A; Feng X; Liao K; Shen D; Hu Z; Chu Y; Lu J; Su J; Gui B; Duan Q; Zhang S; Shao H
Int J Antimicrob Agents; 2015 May; 45(5):485-90. PubMed ID: 25600890
[TBL] [Abstract][Full Text] [Related]
28. Epidemiology and antimicrobial susceptibility profiles of Gram-negative bacteria causing urinary tract infections in the Asia-Pacific region: 2009-2010 results from the Study for Monitoring Antimicrobial Resistance Trends (SMART).
Lu PL; Liu YC; Toh HS; Lee YL; Liu YM; Ho CM; Huang CC; Liu CE; Ko WC; Wang JH; Tang HJ; Yu KW; Chen YS; Chuang YC; Xu Y; Ni Y; Chen YH; Hsueh PR
Int J Antimicrob Agents; 2012 Jun; 40 Suppl():S37-43. PubMed ID: 22749057
[TBL] [Abstract][Full Text] [Related]
29. Clonal outbreak caused by VIM-4-producing Proteus mirabilis in a Greek tertiary-care hospital.
Protonotariou E; Poulou A; Politi L; Meletis G; Chatzopoulou F; Malousi A; Metallidis S; Tsakris A; Skoura L
Int J Antimicrob Agents; 2020 Aug; 56(2):106060. PubMed ID: 32574790
[TBL] [Abstract][Full Text] [Related]
30. High prevalence of CTX-M-15 and first report of CTX-M-3, CTX-M-22, CTX-M-28 and plasmid-mediated AmpC beta-lactamase producing Enterobacteriaceae causing urinary tract infections in Bosnia and Herzegovina in hospital and community settings.
Ibrahimagić A; Bedenić B; Kamberović F; Uzunović S
J Infect Chemother; 2015 May; 21(5):363-9. PubMed ID: 25638292
[TBL] [Abstract][Full Text] [Related]
31. Occurrence of ESBL & Amp-C beta-lactamases & susceptibility to newer antimicrobial agents in complicated UTI.
Taneja N; Rao P; Arora J; Dogra A
Indian J Med Res; 2008 Jan; 127(1):85-8. PubMed ID: 18316858
[TBL] [Abstract][Full Text] [Related]
32. Plasmid-mediated AmpC beta-lactamase-producing Escherichia coli causing urinary tract infection in the Auckland community likely to be resistant to commonly prescribed antimicrobials.
Drinkovic D; Morris AJ; Dyet K; Bakker S; Heffernan H
N Z Med J; 2015 Mar; 128(1410):50-9. PubMed ID: 25829039
[TBL] [Abstract][Full Text] [Related]
33. Detection of TEM and CTX-M genes from ciprofloxacin resistant Proteus mirabilis and Escherichia coli isolated on urinary tract infections (UTIs).
Rajivgandhi G; Maruthupandy M; Manoharan N
Microb Pathog; 2018 Aug; 121():123-130. PubMed ID: 29778819
[TBL] [Abstract][Full Text] [Related]
34. Prevalence of extended-spectrum β-lactamases, AmpC, and carbapenemases in Proteus mirabilis clinical isolates.
Shaaban M; Elshaer SL; Abd El-Rahman OA
BMC Microbiol; 2022 Oct; 22(1):247. PubMed ID: 36221063
[TBL] [Abstract][Full Text] [Related]
35. IMP-27, a Unique Metallo-β-Lactamase Identified in Geographically Distinct Isolates of Proteus mirabilis.
Dixon N; Fowler RC; Yoshizumi A; Horiyama T; Ishii Y; Harrison L; Geyer CN; Moland ES; Thomson K; Hanson ND
Antimicrob Agents Chemother; 2016 Oct; 60(10):6418-21. PubMed ID: 27503648
[TBL] [Abstract][Full Text] [Related]
36. An Increase in the clinical isolation of acquired AmpC β-lactamase-producing Klebsiella pneumoniae in Korea from 2007 to 2010.
Park MJ; Kim TK; Song W; Kim JS; Kim HS; Lee J
Ann Lab Med; 2013 Sep; 33(5):353-5. PubMed ID: 24003426
[TBL] [Abstract][Full Text] [Related]
37. Molecular Characterization of β-Lactam Resistance and Antimicrobial Susceptibility to Possible Therapeutic Options of AmpC-Producing Multidrug-Resistant
Rubic Z; Soprek S; Jelic M; Novak A; Goic-Barisic I; Radic M; Tambic-Andrasevic A; Tonkic M
Microb Drug Resist; 2021 Feb; 27(2):162-169. PubMed ID: 32429775
[TBL] [Abstract][Full Text] [Related]
38. Prevalence of extended spectrum beta lactamase and molecular detection of blaTEM, blaSHV and blaCTX-M genotypes among Gram negative bacilli isolates from pediatric patient population in Gaza strip.
El Aila NA; Al Laham NA; Ayesh BM
BMC Infect Dis; 2023 Feb; 23(1):99. PubMed ID: 36803466
[TBL] [Abstract][Full Text] [Related]
39. Comparison of European Committee on Antimicrobial Susceptibility Testing (EUCAST) and CLSI screening parameters for the detection of extended-spectrum β-lactamase production in clinical Enterobacteriaceae isolates.
Polsfuss S; Bloemberg GV; Giger J; Meyer V; Hombach M
J Antimicrob Chemother; 2012 Jan; 67(1):159-66. PubMed ID: 21972269
[TBL] [Abstract][Full Text] [Related]
40. Characterization and sequence analysis of extended-spectrum-{beta}-lactamase-encoding genes from Escherichia coli, Klebsiella pneumoniae, and Proteus mirabilis isolates collected during tigecycline phase 3 clinical trials.
Jones CH; Tuckman M; Keeney D; Ruzin A; Bradford PA
Antimicrob Agents Chemother; 2009 Feb; 53(2):465-75. PubMed ID: 19015360
[TBL] [Abstract][Full Text] [Related]
[Previous] [Next] [New Search]
